Society of Diabetic Nephropathy Prevention Journal of Preventive Epidemiology 2476-3934 6 1 2021 01 01 Treatment of COVID-19 by CD24FC; a mini-review to the current knowledge e04 e04 10.34172/jpe.2021.04 EN Ghazal Ghasempour Dabaghi https://orcid.org/0000-0001-9850-874X Mehrdad Rabiee Rad https://orcid.org/0000-0001-6800-6925 Lillian Saberian https://orcid.org/0000-0003-4264-2338 Journal Article 10.34172/jpe.2021.04 2021 02 10 2021 05 04 The severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is already known for its respiratory infection, but it involved more organs such as the kidney, liver, and heart. Most of the patients with COVID-19 have mild symptoms, but 5% of cases are admitted to an intensive care unit (ICU) for severe symptoms, including multi-organ failure and septic shock. Excessive immune responses play an essential role in sepsis development and are associated with worse prognosis in COVID-19 patients. Consequently, reduction of these immune responses may be helpful for managing COVID-19 patients. In this mini-review, we discuss the prospective role of CD24FC, as a recombinant protein with immunomodulatory function, in the treatment of COVID-19 patients and its mechanism of action in the regulation of the immune system.